Form 4: Seres Therapeutics Director Claire Fraser Acquires Stock Options

Director Claire Fraser acquired stock options for 60,000 shares of Seres Therapeutics common stock on April 4, 2024.

Summary

• On April 4, 2024, Claire Fraser, a director of Seres Therapeutics, acquired stock options to purchase 60,000 shares of the company's common stock.
• The exercise price of the stock options is $0.76 per share.
• The options vest fully on the earlier of April 4, 2025, or the day before the company's 2025 annual meeting of shareholders.
• The options expire on April 3, 2034.
• Following the transaction, Ms. Fraser directly owns derivative securities for 60,000 shares.

Sentiment

Score: 5

Explanation: Neutral sentiment as it's a standard disclosure of stock option acquisition by a director. It doesn't inherently indicate positive or negative performance.

Positives

• The acquisition of stock options by a director could be seen as a positive sign, indicating confidence in the company's future performance.

Industry Context

Form 4 filings are routine disclosures required by the SEC to provide transparency into the transactions of company insiders. This filing indicates a director's acquisition of stock options, which is a common form of executive compensation.

Stakeholder Impact

• The acquisition of stock options by a director may have a minor positive impact on shareholder sentiment.

Key Dates